Wall Street Zen Upgrades Lumexa Imaging (NASDAQ:LMRI) to Buy

Lumexa Imaging (NASDAQ:LMRI) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Several other equities research analysts have also recently commented on LMRI. Deutsche Bank Aktiengesellschaft set a $16.00 target price on Lumexa Imaging in a research note on Thursday, August 13th. UBS Group reiterated a “strong-buy” rating on shares of Lumexa Imaging in a report on Monday, September 28th. Weiss Ratings reiterated a “sell (d)” rating on shares of Lumexa Imaging in a research report on Tuesday, September 22nd. KeyCorp assumed coverage on Lumexa Imaging in a report on Thursday, September 24th. They set an “overweight” rating and a $18.00 price objective for the company. Finally, Barclays upped their target price on shares of Lumexa Imaging from $9.00 to $13.00 and gave the company an “overweight” rating in a research report on Friday, August 28th. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Lumexa Imaging has an average rating of “Buy” and an average price target of $16.00.

Lumexa Imaging Price Performance

Shares of LMRI stock opened at $10.32 on Friday. Lumexa Imaging has a 1 year low of $6.45 and a 1 year high of $19.45. The firm’s 50 day moving average is $11.30 and its 200-day moving average is $10.28. The firm has a market capitalization of $991.44 million and a price-to-earnings ratio of -21.06. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 1.40.

Lumexa Imaging (NASDAQ:LMRI) last issued its quarterly earnings results on Wednesday, August 12th. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.17. The company had revenue of $264.16 million during the quarter. Lumexa Imaging has set its FY 2026 guidance at 0.710-0.770 EPS. Sell-side analysts forecast that Lumexa Imaging will post 0.25 EPS for the current fiscal year.

Institutional Investors Weigh In On Lumexa Imaging

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Strs Ohio acquired a new position in Lumexa Imaging in the first quarter valued at about $38,000. PNC Financial Services Group Inc. acquired a new position in shares of Lumexa Imaging during the 1st quarter worth about $63,000. Principal Financial Group Inc. increased its stake in shares of Lumexa Imaging by 1.2% in the 1st quarter. Principal Financial Group Inc. now owns 664,136 shares of the company’s stock valued at $5,712,000 after acquiring an additional 7,875 shares during the last quarter. State of Wyoming bought a new stake in shares of Lumexa Imaging in the 1st quarter valued at about $91,000. Finally, AXQ Capital LP acquired a new stake in shares of Lumexa Imaging in the 2nd quarter valued at approximately $128,000.

About Lumexa Imaging

Lumexa Imaging, Inc (NASDAQ: LMRI) is a U.S. healthcare services company focused on outpatient diagnostic imaging. The company operates and supports imaging centers that provide noninvasive services used to detect, diagnose and monitor medical conditions.

Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and other diagnostic imaging procedures. Lumexa also works with radiologists and referring healthcare providers to deliver image interpretation and related clinical services.

The company’s operations are primarily located in the United States, serving patients through a network of outpatient imaging facilities and affiliated radiology practices.